Zhi-Ying Qian

Learn More
OBJECTIVE Endostar® (Rh-endostatin injection) is a new recombinant human endostatin developed by Shandong Simcere-Medgenn Bio-Pharmaceutical Co., Ltd in China. This study was performed to evaluate the efficacy and safety of Endostar plus leucovorin calcium/ 5-fluorouracil/oxaliplatin (FOLFOX4) in treating patients with advanced colorectal cancer. METHODS(More)
PURPOSE To investigate whether it is safe to use leucogen tablets 60 mg three times per day (180 mg for a day) and whether this regimen could reduce the incidence of febrile neutropenia caused by chemotherapy. METHODS This prospectively designed study focused on the safety and effectiveness of leucogen tablets 60mg three times per day for a group of(More)
PURPOSE To highlight the potential factors that could predict the response rate of patients with metastatic colorectal cancer (mCRC) treated with pemetrexed combined chemotherapy after first- or second-line chemotherapy using the FOLFOX regimen. MATERIALS AND METHODS Between January 2007 and July 2014, 54 patients diagnosed and pathologically-confirmed(More)
  • 1